Search Videos and More
Video
Dana-Farber’s Momentum of Discovery
William G. Kaelin Jr., MD won the Nobel Prize for discovering how cancer grows and multiplies by hijacking the body’s oxygen-sensing system, which led to a new class of oxygen-regulating drugs.
News
Genetic Testing, Precision Therapy Spell Success for Young Patient with Rare Syndrome
In a recent case study in the New England Journal of Medicine, researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center describe how a drug targeting the genetic roots of the patient’s condition — an agent based on Nobel Prize-winning research by a Dana-Farber scientist — has caused new tumors in the patient to shrivel, her high blood pressure and headaches to ease, and her polycythemia to relent.
Symposium
2021 ASH Highlights
Review Dana-Farber Cancer Institute faculty highlights from the 63rd Annual Meeting of the American Society of Hematology (ASH).
News
Scientists Identify Potential Target in Ewing Sarcoma Cells
Investigators led by Dana-Farber Cancer Institute’s Kimberly Stegmaier, MD, have discovered that knocking out a protein regulator in Ewing sarcoma cells causes the tumor cells to die from an overdose of a cancer-promoting protein.
News
Immunotherapy Combination Shown to Benefit Some Patients with Non-Small Cell Lung Cancer Resistant to Single Immunotherapy
A combination of two drugs that open the floodgates to an immune system attack on cancer curtailed tumor growth in some patients with non-small cell lung cancer (NSCLC) that was resistant to a single immunotherapy agent, results from a recent clinical trial show.
News
Venetoclax Added to Chemotherapy Improves Outcomes in Type of Leukemia
Adding the BCL-2 inhibitor drug venetoclax to a combination chemotherapy regimen significantly improved outcomes in Richter’s syndrome, a rare but deadly complication that develops in some patients with chronic lymphocytic leukemia (CLL), according to a study led by Dana-Farber investigators.
Symposium
2021 SABCS Highlights
Dana-Farber Cancer Institute faculty highlights from the 2021 San Antonio Breast Cancer Symposium.
News
Immunotherapy Combination Shows Significant Benefit for Patients with Advanced Melanoma
A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial involving 714 patients.
Video
Inadequate SARS-COV-2 Vaccine Effectiveness in Patients with Multiple Myeloma: A Large Nationwide Veterans Affairs Study
Dana-Farber Cancer Institute's Nikhil C. Munshi, MD, details study looking at COVID-19 vaccine effectiveness in patients with multiple myeloma. Research presented at ASH21.
Video
Blood Cancer Research: Clinical Trial Helps Younger Patient
A patient shares her journey getting diagnosed with chronic lymphocytic leukemia in her 30's. Dana-Farber Cancer Institute's Matthew Davids, MD, MMSc, enrolled her on a clinical trial and details the results of that study. The research is now getting presented at ASH21.
News
ASH 2021 Highlights - CME
Register for 2021 ASH Highlights CME
Video
New Study Reveals Elevated Rates of Blood Cancer Precursor Condition in Groups at High Risk for Multiple Myeloma
Dana-Farber Cancer Institute research shows elevated rates of a blood cancer precursor condition in groups at high risk for multiple myeloma.